¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dopamine hydrochloride"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® dopamine ÇÑ±Û µµÆÄ¹Î
¼³¸í   
  È÷µå·Ï½ÃƼ¶ó¹ÎÀ¸·Î¼­ »ý¸®È°¼º ¾Æ¹Î-Ä«Å×ÄݾƹÎÀÇ ÀÏÁ¾. ºÐÀÚ½ÄÀºC18H11NO2, ºÐÀÚ·®Àº 153.18ÀÌ´Ù. µ¿½Ä¹°¿¡ Á¸ÀçÇϴ ¾Æ¹Ì³ë»êÀÇ Çϳª·Î, Àڿܼ± ÀÛ¿ëÀ¸·Î Æ¼·Î½Å¿¡¼­ Çü¼ºµÇ°Å³ª L-DopaÀǠŻź»ê¿¡ ÀÇÇØ Ã¼³»¿¡¼­ »ý»êµÈ´Ù. ¸á¶ó´Ñ »ö¼Ò ÇÕ¼º °úÁ¤ÀÇ Áß°£ ¹°Áú·Î Äá°ú ½Ä¹°¿¡ ÀúÀåµÇ¾î ÀÖ´Ù. ³ú½Å°æ ¼¼Æ÷ÀÇ ÈïºÐ Àü´Þ¿¡ Áß¿äÇÑ ±¸½ÇÀ» ÇÑ´Ù. µµÆÄ¹Î¥â-»êÈ­È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ³ë¸£¾Æµå·¹³¯¸°ÀÌ µÈ´Ù. ºÎ½Å¼öÁú-³ú-±³°¨½Å°æ°è-Æó-ÀÛÀºÃ¢ÀÚ-°£ µî¿¡µµ ¸¹ÀÌ Æ÷ÇԵǾî ÀÖ´Ù. ÆÄŲ½¼ ÁõÈıºÀÇ °æ¿ì ³ú ¾ÈÀÇ µµÆÄ¹Î ·®ÀÌ °¨¼ÒµÇ¸ç, ³úÁÙ±âÀÇ ÁÙ¹«´Ìü¿¡´Â ³ë¸£¾Æµå·¹³¯¸°º¸´Ù µµÆÄ¹ÎÀÌ ´Ù·® Æ÷ÇԵǾî ÀÖÀ½À» º¼ ¼ö Àִٴ Á¡¿¡¼­ µµÆÄ¹Î ÀÚü°¡ À̸¥¹Ù Ä«Å×ÄݾƹÎÀ» ÇÔÀ¯Çϴ ÀÛµ¿¼º ´º·±ÀÇ ½Å°æÀü´Þ¹°Áú·Î¼­ ÀÛ¿ëÇϰí ÀÖÀ½ÀÌ ºÐ¸íÇØÁ³´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopamine
    µµÆÄ¹Î
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • chloroquine hydrochloride
    ¿°»êŬ·Î·ÎÄý
  • ethylnorepinephrine hydrochloride
    ¿°»ê¿¡Æ¿³ë¸£¿¡Çdz×ÇÁ¸°
  • hydrochloride
    ¿°»ê¿°
  • naloxone hydrochloride
    ³¯·Ï¼Õ
  • piperoxane hydrochloride
    ¿°»êÇÇÆä·Ï»ê
  • pyridoxine hydrochloride
    ¿°»êÇǸ®µ¶½Å
  • quinacrine hydrochloride
    Äû³ªÅ©¸°È÷µå·ÎŬ·Î¶óÀ̵å
  • verapamil hydrochloride
    º£¶óÆÄ¹Ð¿°»ê¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • verapamil hydrochloride
    ¿°»êº£¶óÆÄ¹Ð, º£¶óÆÄ¹ÐÈ÷µå·ÎŬ·Î¶óÀ̵å
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • dopamine
    µµÆÄ¹Î
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopamine
    µµÆÄ¹Î
  • chloroquine hydrochloride
    ¿°»êŬ·Î·ÎÄý
  • ethylmorphine hydrochloride
    ¿¡Æ¿¸ð¸£ÇÉ¿°»ê¿°
  • ethylnorepinephrine hydrochloride
    ¿°»ê¿¡Æ¿³ë¸£¿¡Çdz×ÇÁ¸°
  • piperoxane hydrochloride
    ¿°»êÇÇÆä·Ï»ê
  • pyridoxine hydrochloride
    ¿°»êÇǸ®µ¶½Å
  • quinacrine hydrochloride
    Äû³ªÅ©¸°ÇÏÀ̵å·ÎŬ·Î¶óÀ̵å
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Dopamine
    µµÆÄ¹Î
  • harmol hydrochloride
    ¿°»êÇϸ£¸ô.
  • phentolamine hydrochloride
    ¿°»ê(ç¤ß«)ÆæÅç¶ó¹Î.
  • phenylephrine hydrochloride
    ¿°»êÆä´Ò ¿¡ÇÁ¸°.
  • piperoxane hydrochloride
    ¿°»êÇÇÆä·Ï»ê.
  • pyridoxine hydrochloride
    ¿°»ê(ç¤ß«)ÇǸ® µ¶½Å.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopamine
  • dopamine agonist
    µµÆÄ¹Î È¿ÇöÁ¦(üùúÞð¥)
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡¼ö¿ëü È¿ÇöÁ¦
  • dopamine hypothesis
    µµÆÄ¹Î °¡¼³
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü(áôé»ô÷)
  • dopamine receptor antagonist
    µµÆÄ¹Î ¼ö¿ëü ±æÇ×Á¦
  • dopamine-beta-hyroxylase
    µµÆÄ¹Î º£Å¸ È÷µå·Ï½Ç¶óÁ¦
  • cassantin =diethazine hydrochloride
    ¿°È­µð¿¡ ŸÁø.
  • cinchonamina hydrochloride
    ¿°»ê(ç¤ß«)½ÅÄÚ³ª¹Î.
  • cocaine hydrochloride
    ¿°»ê(ç¤ß«)ÄÚÄ«ÀÎ.
  • ephedrine hydrochloride
    ¿°»ê(ç¤ß«)¿¡Æäµå¸°.
  • ethylmorphine hydrochloride
    ¿¡Æ¿¸ð¸£ÇÉ¿°»ê¿°.
  • ethylnorepinephrine hydrochloride
    ¿°»ê(ç¤ß«)¿¡Æ¿³ë¸£¿¡Çdz×ÇÁ¸°.
  • harmol hydrochloride
    ¿°»êÇϸ£¸ô.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • emetine hydrochloride
    ¿¡¸ÞƾÇÏÀ̵å·ÎŬ·Î¶óÀ̵å
  • quinacrine hydrochloride (Atabrine)
    Äû³ªÅ©¸°ÇÏÀ̵å·ÎŬ·Î¶óÀ̵å(¾ÆÅº기)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopamine
    µµÆÄ¹Î
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Cyclo C cyclocytidine hydrochloride
DBI development at birth index; phenformin hydrochloride
DHAD mitoxantrone hydrochloride
EHC enterohepatic circulation; enterohepatic clearance; essential hypercholesterolemia; ethylhydrocuprei...
Special K Ketamine hydrochloride
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AAPH 2'-azobis(2-amidinopropane) hydrochloride
TMB-8 3,4,5,-trimethoxy benzoate hydrochloride
TMB-8 8-(N,N-diethylamino)-octyl-(3,4,5-trimethoxy) benzoate hydrochloride
CPZ Chlorpromazine hydrochloride
GdnHCl guandine hydrochloride
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dopamine
    µµÆÄ¹Î
    1. ½Å°æ Àü´Þ ¹°Áú·Î½á Substantia nigra¿¡¼­ ºÐºñµÇ¸ç, ÈïºÐÀ» ¾ïÁ¦ÇÑ´Ù. 2. ÇÏÀ̵å·Ï½Ã ŸÀ̶ó¹ÎÀ¸·Î¼­ µµÆÄÀÇ Å»Åº»ê¿¡ ÀÇÇÏ¿© ü³»¿¡¼­ »ý»êµÈ´Ù. ³ë¸£¿¡Çdz×ÇÁ¸°ÀÇ ÇÕ¼º Áß°£ »ê¹°ÀÌ´Ù. ÁßÃ߽Űæ°è¿¡¼­ ½Å°æÀü´Þ ¹°Áú·Î¼­ ÀÛ¿ëÇÑ´Ù.
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡ ¼ö¿ëü È¿ÇöÁ¦
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
  • dopamine-beta-hyroxylase
    µµÆÄ¹Î º£Å¸ È÷µå·Ï½Ç¶óÁ¦
  • striatal dopamine

    striate body neurosis

    ¼±Á¶Ã¼ ½Å°æÁõ
  • acecainide hydrochloride
    ¿°»ê ¾Æ¼¼ÄÉÀ̳ªÀ̵å
    Ç׺ÎÁ¤¸Æ¼º ½ÉÀå ¾ïÁ¦Á¦.
  • bupivacaine hydrochloride
    ¿°»ê ºÎÇǹÙÄÉÀÎ
    ¹é»ö °áÁ¤¼º ºÐ¸». ¸»ÃʽŰæ Â÷´ÜÁ¦, ħÀ±, ±³°¨½Å°æ, ¹ÌÃø, °æ¸·¿Ü Â÷´Ü µî¿¡ »ç¿ëµÈ´Ù.
  • buspirone hydrochloride
    ¿°»ê ºÎ½ºÆÄÀÌ·Ð
    ½Å°æ¾ÈÁ¤Á¦.
  • butaclamol hydrochloride
    ¿°»êºÎŸŬ¶ó¸ô
    ½Å°æ¾ÈÁ¤Á¦.
  • butamisole hydrochloride
    ¿°»ê ºÎŸ¸ñ¼¼ÀÎ
    ½Å°æ¾ÈÁ¤Á¦.
  • butoxamine hydrochloride
    ¿°»ê ºÎÅå»ç¹Î
    ¾Æµå·¹³¯¸° º£Å¸ ¼ö¿ëü Â÷´ÜÁ¦.
  • chlorphenoxamine hydrochloride
    ¿°»ê Ŭ·Î¸£Ææ¿Á»ç¹Î
    2-[1-
  • cocaine hydrochloride
    ¿°»ê ÄÚÄ«ÀÎ
  • diltiazem hydrochloride
    ¿°»ê ´ÙÀÏÆ¼¾ÆÁª
    °ü»ó Ç÷°ü È®ÀåÁ¦, Çù½ÉÁõÀÇ ´ëÁõ¿ä¹ý¿¡ »ç¿ëÇÑ´Ù,
  • dimethisoquin hydrochloride
    ¿°»ê ´ÙÀÌ¸ÞÆ¼¼ÒÄý
    ¹é»ö ¹«ÃëÀÇ ºÐ¸». ¹°, ¾ËÄÝ, Ŭ·Î·ÎÆ÷¸§¿¡³ìÀ¸¸ç ±¹¼Ò¸¶ÃëÁ¦·Î »ç¿ëµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
dopamine hydrochloride A biogenic amine and neural transmitter substance, used as a vasopressor agent for treatment of shock.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptors, dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, dopamine d1 A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action.
(12 Dec 1998)
receptors, dopamine d2 A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action.
(12 Dec 1998)
dopamine <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline.
Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance
Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output
Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min.
Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias
(15 Mar 2000)
dopamine agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
(12 Dec 1998)
dopamine agonists Drugs that bind to and activate dopamine receptors.
(12 Dec 1998)
dopamine antagonists Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup.
(12 Dec 1998)
dopamine beta-hydroxylase <enzyme> Chemical name: 3,4-Dihydroxyphenethylamine, ascorbate:oxygen oxidoreductase (beta-hydroxylating)
Registry number: EC 1.14.17.1
(12 Dec 1998)
dopamine beta-monooxygenase A copper-containing enzyme catalyzing oxidation of ascorbate and 3,4-dihydroxyphenylethylamine simultaneously by O2 to yield norepinephrine, dehydroascorbate, and water; a crucial step in catecholamine metabolism.
Synonym: dopamine beta-hydroxylase.
(05 Mar 2000)
dopamine uptake inhibitors Drugs that block the transport of dopamine into axon terminals or into storage vesicles within terminals. most of the adrenergic uptake inhibitors also inhibit dopamine uptake.
(12 Dec 1998)
adiphenine hydrochloride Alpha-Phenylbenzeneacetic acid 2-(diethylamino)ethyl ester hydrochloride;a spasmolytic agent used to decrease spasm of the biliary tract, gastrointestinal tract, uterus, and ureter.
(05 Mar 2000)
alfentanil hydrochloride C21H32N6O3 -HCl -H2O;a very potent, short acting narcotic agonist analgesic used as an anaesthetic or as an adjunct in the maintenance of general anaesthesia.
(05 Mar 2000)
alpha-prodine hydrochloride See: alphaprodine.
(05 Mar 2000)
alprenolol hydrochloride The hydrochloride salt of 1-(o-allylphenoxy)-3-(isopropylamino)propan-2-ol; a beta-receptor blocking agent, used for the treatment of cardiac arrhythmias.
(05 Mar 2000)
amantadine hydrochloride 1-Adamantanamine;an antiviral agent used for influenza; also used to treat parkinsonism where it increases dopamine release and reduces its reuptake into dopaminergic nerve terminals of substantia nigra neurons.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dopamine
    µµÆÄ¹Î(³ú½Å°æÀÇ Àü´Þ ÀÛ¿ë¿¡ ÇÊ¿äÇÑ ¹°Áú)
  • hydrochloride
    ¿°»ê¿°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á